KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Equity Ratio (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Equity Ratio readings, the most recent being 0.21 for Q1 2026.

  • On a quarterly basis, Equity Ratio rose 25.92% to 0.21 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.21, a 25.92% increase, with the full-year FY2025 number at 0.19, up 41.97% from a year prior.
  • Equity Ratio hit 0.21 in Q1 2026 for Teva Pharmaceutical Industries, up from 0.19 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.22 in Q1 2022 to a low of 0.14 in Q4 2024.
  • Median Equity Ratio over the past 5 years was 0.18 (2025), compared with a mean of 0.18.
  • Biggest five-year swings in Equity Ratio: dropped 26.8% in 2024 and later skyrocketed 41.97% in 2025.
  • Teva Pharmaceutical Industries' Equity Ratio stood at 0.2 in 2022, then dropped by 4.33% to 0.19 in 2023, then dropped by 26.8% to 0.14 in 2024, then skyrocketed by 41.97% to 0.19 in 2025, then increased by 5.81% to 0.21 in 2026.
  • The last three reported values for Equity Ratio were 0.21 (Q1 2026), 0.19 (Q4 2025), and 0.18 (Q3 2025) per Business Quant data.